Clinical safety
Monitoring intervals and observation windows by delivery mode
A single monitoring protocol cannot cover a flood-dose IV administration and a telehealth microdose regimen. Route, formulation, dosing strategy and setting each change the shape of the risk curve, and therefore how often vitals are taken and how long the patient is observed.
What changes with the delivery mode
- Route and formulation change absorption and time to peak: intravenous administration reaches peak within minutes, oral HCl over hours, and sublingual and root bark preparations are slower and less predictable.
- Total alkaloid extract and root bark contain other iboga alkaloids beyond ibogaine, so dose equivalence with purified HCl cannot be assumed.
- Dosing strategy changes the duration of exposure: a flood dose concentrates risk into one long session, while titrated and booster schedules spread it across repeated windows that each need their own checks.
- Setting changes what is possible: an inpatient session can use continuous cardiac monitoring; a telehealth microdose protocol relies on patient-reported readings, which changes both thresholds and escalation paths.
- Bradycardia and hypotension are expected effects rather than surprises, so the protocol should state what degree is tolerated and at what point it is escalated.
Shape of a monitoring schedule
The pattern below is the structure most protocols share: dense observation through the peak, then widening intervals while the patient remains under observation, and a defined discharge criterion rather than a fixed clock time. Exact intervals, doses and windows are set by each programme's medical director against its own jurisdiction's guidance.
| Delivery mode | Peak risk period | Monitoring shape |
|---|---|---|
| IV ibogaine HCl, flood | Minutes to the first hours | Continuous cardiac monitoring through peak, frequent vitals, extended observation well past subjective resolution |
| Oral ibogaine HCl, flood | First several hours | Pre-dose baseline, dense vitals through the peak, widening intervals overnight, next-day ECG before discharge |
| Oral ibogaine HCl, titrated | Each incremental dose | Checks before and after every increment, with predefined stop criteria rather than a target dose |
| Sublingual iboga total alkaloid | Slower and less predictable onset | Longer pre-peak observation, conservative dose escalation, same threshold-based escalation as HCl |
| Root bark preparations | Variable and preparation-dependent | Treated as unknown-potency: conservative dosing, extended observation, documented provenance of the material |
| Booster dosing | Each booster window | Repeat pre-dose checks each time, including QTc if the prior session showed prolongation |
| Microdose, supervised or telehealth | Cumulative rather than acute | Scheduled home vitals, daily symptom and mood check-ins, periodic ECG review, clear escalation instructions |
Escalation has to be written before it is needed
The useful protocol is specific about what triggers action and who takes it: which values prompt a repeat measurement, which prompt the prescriber, which prompt emergency services, and what the local emergency pathway actually is. In New Zealand that means 111 for emergencies and Healthline for advice; elsewhere it means the equivalent, configured per deployment rather than assumed.
Adverse events should be recorded against the session that produced them, with the action taken, so the register is usable for review rather than being a list of narratives.
This page describes the structure of monitoring protocols. It is not a dosing guide, does not recommend doses, routes or intervals, and does not replace clinical judgement, cardiac telemetry or emergency care.
Follow-up is part of the protocol
The treatment arc does not end at discharge. Structured follow-up at one week, one month, three months and six months, with the same assessment instruments each time, is what turns a single session into a clinical outcome you can describe. Auto-scored PHQ-9, GAD-7, craving, sleep and mood measures charted against treatment milestones make change visible without a chart review.
Run this in one clinical record
Ibogaine NZ holds screening, monitoring, assessments, adverse events and follow-up for clinics and prescribers in any jurisdiction. 21-day trial, no card required.